{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-064241","form_type":"8-K","ticker":"CRMD","cik":"0001410098","company_name":"CorMedix Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.827026+00:00","generated_at":"2026-06-12T01:25:34.751223+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CorMedix Q2 net loss widens to $11.3M; DefenCath NDA PDUFA date Nov 15, 2023","bullets":["Net loss of $11.3M ($0.25 per share) vs $7.6M loss in Q2 2022, driven by increased R&D and SG&A.","Cash and short-term investments $52.4M at June 30; after July equity offering pro forma cash ~$95M.","DefenCath NDA accepted with PDUFA target date of November 15, 2023; CMS set NTAP up to $17,111 if approved.","Operating expenses increased 43% to $11.8M; R&D up 49% to $4.8M; SG&A up 39% to $7.0M.","Strategic initiative with Boston Medical Center to assess CRBSI incidence and health disparities."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-064241","json":"https://secwatch.observer/filing/0001213900-23-064241.json","markdown":"https://secwatch.observer/filing/0001213900-23-064241.md","text":"https://secwatch.observer/filing/0001213900-23-064241.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410098/000121390023064241/0001213900-23-064241-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410098/000121390023064241/ea183017-8k_cormedix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T01:25:34.751223+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3d13164fa174ee7bb89c3911cf035f109ddb3491","claim":"CorMedix Inc. reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"On August 8, 2023, CorMedix Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390023064241/0001213900-23-064241-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}